MetaCap

Allogene Therapeutics (ALLO) vs Artiva Biotherapeutics (ARTV)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Artiva Biotherapeutics (ARTV) has outperformed Allogene Therapeutics (ALLO) over the past year, gaining 20.8% versus a loss of 49.0%. Allogene Therapeutics is the larger company by market cap ($217.5 million vs $186.9 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALLO-48.97%ARTV+20.77%
+347%+139%-68%
Nov 21, 20251 yearNov 20, 2026
ALLO-77.82%ARTV-68.50%
+38%-28%-94%
Jul 15, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALLO versus ARTV key metrics
MetricALLOARTV
Share price$0.6277$3.78
Market cap$217.48M$186.85M
1-day change-5.88%-1.31%
YTD return-54.18%-11.89%
1-year return-48.97%+20.77%
5-year return-96.51%—
EPS (TTM)$-0.61$-2.85
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$0
Revenue growth (YoY)-100.00%-100.00%
Net income (latest FY)$-190.89M$-83.86M
52-week high$4.46$14.53
52-week low$0.6192$2.96
Distance from 52-week high-85.93%-73.98%
Analyst consensusstrong_buybuy
Avg. price target upside+1333.81%+448.94%
Average volume7.69M792.26K
Shares outstanding346.47M49.43M
Employees150134
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARTV has outperformed ALLO by 69.7 percentage points over the past year.

About Allogene Therapeutics

ALLO stock →

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees

About Artiva Biotherapeutics

ARTV stock →

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees

ALLO vs ARTV FAQ

Which is bigger, Allogene Therapeutics or Artiva Biotherapeutics?

Allogene Therapeutics (ALLO) is larger, with a market capitalization of $217.48M compared with $186.85M for Artiva Biotherapeutics (ARTV).

Which stock has performed better over the past year, ALLO or ARTV?

ARTV returned +20.77% over the past 12 months, compared with -48.97% for ALLO (price return, excluding dividends). Past performance does not predict future results.

Are Allogene Therapeutics and Artiva Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons